Diabetes Therapy to Improve BMI and Lung Function in CF

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Cystic FibrosisDiabetes Mellitus
Interventions
DRUG

Insulin Asparte

Insulin asparte given 0.5 units per carb per meal

DRUG

Repaglinide

0.5mg tab with meals tid

Trial Locations (7)

55455

University of Minnesota Medical Center, Minneapolis

94304

Stanford University, Palo Alto

01199

Baystate Medical Center, Springfield

15213-2583

Children's Hospital of Pittsburgh, Pittsburgh

37232-2650

Vanderbilt University Medical Center, Nashville

84132-4701

University of Utah, Salt Lake City

M5B 1W8

St. Michael's Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

Novo Nordisk A/S

INDUSTRY

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00072904 - Diabetes Therapy to Improve BMI and Lung Function in CF | Biotech Hunter | Biotech Hunter